Wall Street analyst estimates for CDT Equity Inc. (CDT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clin...
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.01 |
| EV / EBITDA | 3.99 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $283000 | $111000 | $90000 | $3.4M | $5.1M |
| Selling, General & Admin | $2.9M | $3.0M | $5.2M | $12.0M | $31.7M |
| Operating Expenses | $3.2M | $3.2M | $5.3M | $15.4M | $36.8M |
| Operating Income | -$3.2M | -$3.2M | -$5.3M | -$15.4M | -$36.8M |
| EBITDA | -$3.7M | -$4.9M | $3.1M | -$15.8M | -$36.5M |
| Interest Expense | 0 | 0 | $211000 | $1.5M | $319000 |
| Pre-tax Income | -$3.7M | -$4.9M | $2.8M | -$17.8M | -$39.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$3.7M | -$4.9M | -$535000 | -$17.8M | -$39.2M |
| EPS | $-7.50 | $-2013.60 | $-239.70 | $-6159.30 | $-117.79 |
| EPS (Diluted) | $-7.50 | $-2013.60 | $-2676.00 | $-6159.30 | $-117.79 |
| Shares Outstanding (Diluted) | $576 | $2427 | $2263 | $2890 | $333000 |
Price
| Price | $0.20 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Related companies: CCM · COCH · ENVB · HEPA · LIXT · NIVF · PTPI
Explore sector: Healthcare · Biotechnology
More sections of CDT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks